dc.contributor.author |
Gudiksen KL |
|
dc.contributor.author |
King JS |
|
dc.date.accessioned |
2020-11-12T03:50:58Z |
|
dc.date.available |
2020-11-12T03:50:58Z |
|
dc.date.issued |
2019 |
|
dc.identifier.issn |
0093-1748 |
|
dc.identifier.uri |
http://hdl.handle.net/2292/53582 |
|
dc.description.abstract |
In this article, we analyze the variety of laws recently passed by state legislatures to address rising prescription drug costs, as well as the litigation challenges brought by pharmaceutical manufacturers to many of these laws, and the ever-expanding legal thicket that states must traverse to control drug prices. We describe how states have used their state-employee benefits programs alone or within larger cost-saving initiatives to control drug costs and discuss how they could be expanded to private insurers. Finally, we will offer a series of recommendations to state policymakers regarding options for controlling prescription drug prices. |
|
dc.publisher |
Taylor & Francis |
|
dc.relation.ispartofseries |
The Journal of legal medicine |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
1117 Public Health And Health Services |
|
dc.subject |
1801 Law |
|
dc.title |
The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1080/01947648.2019.1645541 |
|
pubs.begin-page |
95 |
|
pubs.volume |
39 |
|
dc.date.updated |
2020-10-15T00:22:25Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.end-page |
95 |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
|
pubs.elements-id |
818130 |
|